Sublingual Immunotherapy: Is it a Viable Option to Subcutaneous Immunotherapy when Treating Allergic Rhinitis? by Kesterson, David Ryan
University of North Dakota
UND Scholarly Commons
Physician Assistant Scholarly Project Posters Department of Physician Studies
2016
Sublingual Immunotherapy: Is it a Viable Option to
Subcutaneous Immunotherapy when Treating
Allergic Rhinitis?
David Ryan Kesterson
University of North Dakota
Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Allergy and Immunology Commons
This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.
Recommended Citation
Kesterson, David Ryan, "Sublingual Immunotherapy: Is it a Viable Option to Subcutaneous Immunotherapy when Treating Allergic
Rhinitis?" (2016). Physician Assistant Scholarly Project Posters. 78.
https://commons.und.edu/pas-grad-posters/78
Sublingual Immunotherapy: Is it a Viable Option to Subcutaneous 
Immunotherapy when Treating Allergic Rhinitis?
Author: David Ryan Kesterson
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Abstract
Introduction
• AR is a debilitating disease that affects millions of people 
throughout the world. It accounts for numerous office visits thus 
increasing the cost of health care for those who suffer. Many 
treatments are available to manage the symptoms, but only one 
kind of drug has shown success in modifying the disease. 
Symptomatic medications are not curative in nature, so they 
contribute to added cost over a lifetime. SCIT and SLIT are used 
to modify the disease process by desensitizing the body’s 
response to allergens. The purpose of this study is to determine 
whether SLIT is as effective as SCIT in treating AR.
Research Questions
Literature Review




• These findings suggest that treatment with SLIT is an effective 
alternative to SCIT for reducing symptoms associated with AR 
and decreasing the immunologic response. 
• When comparing safety of the two therapies, SLIT had less 
serious adverse events when compared to SCIT. Some minor 
adverse reactions and few systemic reactions were noted with 
SLIT, but SCIT carries a higher risk for anaphylaxis during 
treatments with fatalities being rare. 
• Adherence to treatment was found to have conflicting evidence. 
In many RCTs SLIT showed superiority over SCIT for adherence, 
but information from large pharmacy refill databases showed that 
more patients on SCIT were continuing treatment after three years 
when compared to SLIT. 
• SLIT and SCIT showed to have significant cost reduction over 
placebo and studies have shown that SLIT is slightly favorable 
over SCIT.
• Background:  Allergic rhinitis (AR) is a very common debilitating 
disease that can be detrimental to one’s lifestyle, work, and home life. 
Immunotherapy is the only treatment option that has disease modifying 
capabilities with a proper therapeutic regimen. Subcutaneous 
immunotherapy (SCIT) was developed over 100 years ago and has been 
the gold standard in immunotherapy for many years in the United 
States. During these years many adverse reactions have been reported 
with SCIT along with non-adherence to total treatment. The 
introduction of sublingual immunotherapy (SLIT) over 20 years ago 
gave providers a promising alternative to SCIT. 
• Method:  A review of literature was performed to gain information on 
studies comparing SLIT to SCIT for treating allergic rhinitis. This 
review includes head to head clinical outcomes from systematic 
reviews and meta-analyses. Efficacy, cost, adherence, and adverse 
reactions was analyzed between SLIT and SCIT to determine if SLIT is 
a practical treatment option. 
• Results:  The results indicate that treatment with SLIT is comparable to 
SCIT. SLIT significantly reduces the symptoms of AR with -0.49 SMD 
and SCIT with -0.73 SMD. Both SCIT and SLIT are generally safe 
medications when administered properly. SCIT demonstrates a higher 
risk of systemic reactions with anaphylaxis occurring 0.72% versus 
0.33% in placebo. Comparative data shows that SLIT is an effective 
alternative to SCIT and has equivalent to better adherence to treatment.
• Application:  It is important for providers to understand the detrimental 
effects of AR and treat the disease process aggressively. AR may be 
commonly misdiagnosed, so understanding the disease process and how 
it can mimic others will promote better treatment outcomes and patient 
satisfaction. Ideally, SLIT will be seen as a viable option compared to 
SCIT for treating allergic rhinitis in patients where symptomatic 
treatment options do not suffice.
• In patients with allergic rhinitis, is sublingual immunotherapy 
effective for reducing allergic rhinitis when compared to 
subcutaneous immunotherapy?
• SLIT versus SCIT in safety, adherence, and cost effectiveness.
• Current literature was studied to evaluate all information 
containing sublingual immunotherapy and subcutaneous 
immunotherapy when treating allergic rhinitis in the form of 
RCTs, Cochrane meta-analyses, non-Cochrane meta-analyses, 
systematic literature reviews, and large pharmacy refill database 
studies. 
• Pathophysiology
– AR is a chronic disease where allergens trigger an allergic 
response
– Exposure to certain extrinsic proteins can lead to specific IgE to 
the protein in a Type I allergic reaction.
– Specific immunotherapy desensitizes the body’s response. 
• Efficacy between SLIT and SCIT
– In one SCIT meta-analysis, 51 RCTs were examined totaling 
2,871 patients. It was found that there was a clinically 
significant reduction in symptomatic score with -0.73 SMD and 
medication score with -0.57 SMD (Aboshady et al. 2014)
– In one SLIT meta-analysis, 49 RCTs were examined totaling 
4,589 patients. It showed a clinically significant reduction in 
symptomatic score  with  -0.49 SMD (P<0.001) and medication 
score with -0.32 SMD (P<0.001) (Aboshady et al. 2014). 
• Safety between SLIT and SCIT
– Aboshady et al. 2014, found in a SCIT meta-analysis that 8% 
and 7% of patients in the treated groups experienced grades II 
and III systemic reactions with anaphylaxis (grade IV) 
occurring in 3 cases (0.72%)
– In one SLIT meta-analysis, it was shown that it generally 
produces minor local reactions of the gastrointestinal system. 
Calderón et al. 2013, conducted a study that calculated the 
amount of doses given for SLIT to be at one billion worldwide 
from 2000 to 2010 and only found eleven case reports for 
anaphylaxis with no deaths. 
• Adherence between SLIT and SCIT (Bender 2015)
– Three large pharmacy refill databases showed 
• 53% of SCIT patients being non-adherent after year one and 
84% being non-adherent by the third year of treatment.
• 56.3% of SLIT patients were non-adherent after year one and 
86.6% were non-adherent by the third year.
• Cost effectiveness between SLIT and SCIT (Dranitsaris et al. 
2014)
– Monthly drug cost in double-blind placebo controlled RCTs 
• Oralair $1,003 1st year, 2nd and 3rd $1,983.84.
• Grazax $2,171 1st year, 2nd and 3rd $4,327.
• SCIT year-round $3,474 1st year, 2nd and 3rd $2,852.
• SCIT seasonal $1,951 1st year, 2nd and 3rd $3,867. 
• AR is commonly misdiagnosed or overlooked.
• Current clinical practice is through the use of symptomatic drug 
therapy which can be useful in those with less severe AR. 
• Obstacles to immunotherapy: out-of-pocket costs, use of OTC 
drugs, and adherence to long term therapy. 
• Education about the therapy options and potential for cost savings 
long term.
• As a provider, know when to refer and not to refer to an allergist.
– Know what your patient wants long term 
– Know if long term therapy is feasible from a financial stand 
point.
• For those with severe AR perform RAST (IgE antibodies) or skin 
prick test (antigen introduced) to determine triggers and need for 
immunotherapy. 
A genuine thank you is extended to my faculty advisor Terri 
Wold who served as my mentor for this project. I truly 
appreciate your strong vision, tremendous guidance, and 
limitless revisions. Compiling this information in a presentable 
manner would not have been possible without your knowledge 
and advice.
Statement of the Problem
• Insurance deductibles are constantly on the rise and a debilitating 
disease like AR will make out of pocket expenses increase for 
those who suffer. SCIT has been the mainstay for treating severe 
AR, but it can be problematic for patients to continuously go to 
the physician’s office to receive shots when they can take SLIT at 
the convenience of their home. Another factor with traditional 
immunotherapy is safety. More statistical information is needed to 
compare SCIT and SLIT for safety and efficacy so clinicians can 
decide which treatment is best for their patient.
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